Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Iams, MD, MSCI, examined outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer. Adding immunotherapy to platinum-based chemotherapy is an established standard of care for ...

The Food and Drug Administration granted fast track designation to HDP-101 for the treatment of multiple myeloma. The U.S.

NASP data highlight reduction in disease burden among people living with uncontrolled goutGamifant (emapalumab) data showed response rates in ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...

The U.S. Food and Drug Administration (FDA) has granted rare pediatric drug designation for iopofosine-131 in inoperable relapsed or refractory pediatric high-grade glioma (pHGG), according to a news ...

The European Commission’s approvals of TEVIMBRA in lung cancer are based on five randomized Phase 3 studies from the RATIONALE program. At ESMO 2025, BeOne will present new data from two of these ...

Daiichi Sankyo Company, Limited ( OTCPK:DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions October 21, 2025 8:00 AM EDT ...

Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura ® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Johnson & Johnson today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly ...